SEARCH

SEARCH BY CITATION

References

  • Baus, D. & Pfitzner, E. (2006) Specific function of STAT3, SOCS1, and SOCS3 in the regulation of proliferation and survival of classical Hodgkin lymphoma cells. International Journal of Cancer, 118, 14041413.
  • Bhalla, K., Fiskus, W., Herger, B., Rao, R., Ustin, A., Jillella, A. & Atadja, P. (2007) Anti-leukemia activity of histone deacetylase (HDAC) inhibitor LBH589 involves depletion of EZH2 and DNA methyltransferase (DNMT) 1 through disruption of their chaperone association with heat shock protein (hsp) 90. Journal of Clinical Oncology (ASCO Abstracts), A10501.
  • Bolden, J.E., Peart, M.J. & Johnstone, R.W. (2006) Anticancer activities of histone deacetylase inhibitors. Nature Reviews Drug Discovery, 5, 769784.
  • Buglio, D., Georgiakis, G.V., Hanabuchi, S., Arima, K., Khaskhely, N.M., Liu, Y.J. & Younes, A. (2008) Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood, 112, 14241433.
  • Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244.
  • Ellis, L., Pan, L., Smyth, M.J., George, D.J., McCormack, C., Williams-Truax, R., Atadja, P., Zhao, C., Dugan, M., Culver, K., Johnstone, R. & Prince, H.M. (2008) The histone deacetylase inhibitor LBH589 induces responses with associated alterations in gene expression profiles in cutaneous T cell lymphoma. Clinical Cancer Research, 14, 45004510.
  • Maiso, P., Carvajal-Vergara, X., Ocio, E.M., Lopez-Perez, R., Mateo, G., Gutierrez, N., Atadja, P., Pandiella, A. & San Miguel, J.F. (2006) The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Research, 66, 57815789.
  • Niens, M., Visser, L., Nolte, I., Van Der Steege, G., Diepstra, A., Cordano, P., Jarrett, R., Te Meerman, G., Poppema, S. & Van Den Berg, A. (2008) Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22. British Journal of Haematology, 140, 527536.
  • Nishioka, C., Ikezoe, T., Yang, J., Komatsu, N., Bandobashi, K., Taniguchi, A., Kuwayama, Y., Togitani, K., Koeffler, H.P. & Taguchi, H. (2008) Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor kappaB. Leukemia Research, 32, 287296.
  • O’Connor, O.A., Heaney, M.L., Schwartz, L., Richardson, S., Willim, R., MacGregor-Cortelli, B., Curly, T., Moskowitz, C., Portlock, C., Horwitz, S., Zelenetz, A.D., Frankel, S., Richon, V., Marks, P. & Kelly, W.K. (2006) Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. Journal of Clinical Oncology, 24, 166173.
  • Ottmann, O.G., Spencer, A., Prince, H.M., Bhalla, K.N., Fischer, T., Liu, A., Parker, K., Jalaluddin, M., Laird, G., Woo, M., Scott, J.W. & DeAngelo, D.J. (2008) Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan-Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies. Blood (ASH Annual Meeting Abstracts), 112, 958.
  • Skinnider, B. (2002) The role of cytokines in classical Hodgkin lymphoma. Blood, 99, 42834297.
  • Spencer, A., Prince, H.M., De Angelo, D.J., Fischer, T., Bhalla, K., Giles, F., Liu, A., Parker, S., Laird, G., Masson, E., Rediske, J., Scott, J.W. & Oliver, O.G. (2007) Phase IA/II Study of Oral LBH589, a Novel Deacetylase Inhibitor (DACi), Administered on 2 Schedules, in Patients with Advanced Hematologic Malignancies. Blood (ASH Annual Meeting Abstracts), 110, A907.
  • Younes, A., Pro, B., Fanale, M., McLaughlin, P., Neelapu, S., Fayad, L., Wedgwood, A., Buglio, D., Patterson, T., Dubay, M., Li, Z., Martell, R.E., Ward, M.R. & Bociek, R.G. (2007) Isotype-Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin Lymphoma (HL). Blood (ASH Annual Meeting Abstracts), 110, 2566.
  • Zhou, Q., Agoston, A.T., Atadja, P., Nelson, W.G. & Davidson, N.E. (2008) Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. Molecular Cancer Research, 6, 873883.